

TABLE OF CONTENTS

THESIS	ii
RATIFICATION PAGE	iii
STATEMENT PAGE	iv
DEDICATION PAGE	v
FOREWORD	vi
TABLE OF CONTENTS	vii
LIST OF FIGURES	ix
LIST OF TABLES	x
LIST APPENDIXES	xi
ABSTRACT	xii
INTISARI	xii
CHAPTER I INTRODUCTION	1
I.1 Background	1
I.2 Research Purposes	4
I.3 Advantages the Research	4
CHAPTER II LITERATURE REVIEW AND HYPOTHESIS FORMULATION	6
II.1 Alzheimer's Disease (AD)	6
II.1.1 Definition alzheimer's disease	6
II.1.2 AChE	6
II.1.3 AChE mechanism	8
II.1.4 Drug mechanism	10
II.1.5 Donapezil	11
II.1.6 Galantamine	12
II.1.7 Rivastigmine	12
II.1.8 Coumarin compounds	13
II.2 Density Functional Theory (DFT)	13
II.2.1 Definition of density functional theory	13
II.2.2 Hybrid density function	14
II.2.3 Basis set	15
II.3 QSAR	16
II.3.1 Definition of QSAR	16
II.3.2 Validation of QSAR	17
II.3.3 Preconditon of Data in Analysis QSAR	18
II.3.4 Traning and Set data	18
II.3.5 Variable Selection	19
II.3.6 Descriptors	20
II.3.7 Outlier	21
II.3.8 MLR	21
II.3.9 Hypothesis	24
CHAPTER III RESEARCH METHODS	28

III.1. Instruments and Materials	28
III.1.1 Instruments	28
III.1.2 Materials	28
III.2 Procedure	31
III.2.1 Selection for computational method	31
III.2.2 Calculation of electronic and molecular descriptors	31
III.2.3 Data set	31
III.2.4 Development of the QSAR model	32
III.2.5 Validation model	32
III.2.6 Design a new compound	32
CHAPTER IV RESULTS AND DISCUSSION	34
IV.1 Selection of Basis Sets and Methods of Calculation	34
IV.2 Develop Training and Test Sets	40
IV.3 Selection Variables on Internal Validity	41
IV.4 External Validation	43
IV.5 Reference of Design Compound	46
IV.6 Drug Design of A16 VS B04	51
IV.7 Retrosynthesis a Novel Drug Compounds	52
CHAPTER V	57
V.1 Conclusion	57
V.2 Suggestion	57
REFERENCES	58
APPENDIXES	64